Open an account

RADNOSTIX

INIS · OTC

$0.047+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.047

About INIS

Radnostix, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 44 full-time employees. The firm manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. The firm provides contract manufacturing of various drug products as well as radioisotope active pharmaceutical ingredient (API) supply for third party theranostics clients. The firm manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and single photon emission computed tomography (SPECT)/positron emission tomography (PET) imaging systems as well as industrial calibration standards under its RadQual brand. The firm also manufactures Cobalt-60 sealed source products.

Employees
44
Headquarters
Idaho Falls, Idaho
Listed
Aug 14, 1997
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
radnostix.com

INIS key statistics

Market cap
24.87M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
75.12K
Volume
49.95K
Open price
$0.048
High today
$0.0493
Low today
$0.047
52 Week high
$0.11
52 Week low
$0.0302

RADNOSTIX (INIS) at a glance

RADNOSTIX (INIS) last traded at $0.047, with a market cap of 24.87M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.047 and $0.0493. The current price is 0.0% above the day's low and 4.7% below its high.

Volume so far is 49.95K shares, below the average of 75.12K shares a day.

Over the past year RADNOSTIX has ranged from $0.0302 to $0.11, and now sits 21% of the way up that range.

RADNOSTIX met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY25 it reported $0.00 per share against an estimate of $0.00.

INIS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 95.9% on average.

  1. Q4 FY13: reported -$0.01 per share against an estimate of -$0.0816
  2. Q3 FY14: reported $0.00 per share against an estimate of -$0.0009
  3. Q4 FY14: reported $0.00 per share against an estimate of -$0.0008
  4. Q3 FY23: reported $0.00 per share against an estimate of $0.00
  5. Q4 FY23: reported $0.00 per share against an estimate of $0.00
  6. Q2 FY24: reported $0.00 per share against an estimate of $0.00
  7. Q3 FY24: reported $0.00 per share against an estimate of $0.00
  8. Q2 FY25: reported $0.00 per share against an estimate of $0.00

INIS news

  • Press releasePRNewswire

    Radnostix and NANO Nuclear Energy Announce Joint Submission of Letter of Intent to NRC Seeking Consent for Transfer of License SUB-1011, Following Lea County Approval of Property LOI

  • Press releasePRNewswire

    Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear

  • Press releasePRNewswire

    Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition

  • Press releasePRNewswire

    Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

  • Press releasePRNewswire

    Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown

  • Press releasePRNewswire

    Radnostix, Inc. Reports FY2025 Results - Second-Highest Annual Revenue in Company History; Delivers Strong Growth in Calibration & Reference Products and Advances Key Product Launches in 2025

  • Press releasePRNewswire

    Mutual Termination of the Asset Purchase Agreement related to the Radnostix DUF6 Assets

  • Press releasePRNewswire

    International Isotopes Inc. Announces Company Name Change to Radnostix, Inc.

Similar companies

Companies in the same industry as RADNOSTIX

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.